The title compound was obtained from the reaction of 1,3-dimethylpyrimidine-2,4,6-trione, t-butyl isocyanide and dimethyl acetylene dicarboxylate in cold dichloromethane. The yellow solution was refluxed and purified by column chromatography on alumina using a mixture of ethyl acetate and hexane (20:80, v/v) as eluent. The colorless solution was allowed to concentrate slowly at room temperature. Recrystallization from methanol gave crystals suitable for X-ray structure analysis.
Source of material
The title compound was obtained from the reaction of 1,3-dimethylpyrimidine-2,4,6-trione, t-butyl isocyanide and dimethyl acetylene dicarboxylate in cold dichloromethane. The yellow solution was refluxed and purified by column chromatography on alumina using a mixture of ethyl acetate and hexane (20:80, v/v) as eluent. The colorless solution was allowed to concentrate slowly at room temperature. Recrystallization from methanol gave crystals suitable for X-ray structure analysis.
Discussion
A large number of pyrimidine derivatives are reported to exhibit antimycobacterial, antitumor, antiviral, anticancer, anti-inflammatory, analgesic, antifolate, antimicrobial, anti-fungal, antiproliferative and antihistaminic activities [1] . There are some new reports on crystal structures of pyrimidine derivatives [2] [3] [4] . The crystal structure analysis of the title compound was performed in view of its good stability.
In the crystal structure, the molecule is stabilized by one intramolecular NH···O hydrogen bond. Details of the N10H1N···O2 bond are: (5) 
